Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474353 · ClinicalTrials.gov registry record · Phase 1
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04474353: Completed Phase 1 study, sponsored by Stanford University.
NCT04474353 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474353, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma (GBM).
Interventions
- DRUG Temozolomide
- DRUG Gadolinium
- DEVICE Optune
- RADIATION Stereotactic radiosurgery (SRS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04474353
The ClinicalTrials.gov registry entry for NCT04474353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT04474353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04474353 about?
NCT04474353 is a clinical study titled "Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma". The purpose of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma (GBM).
What is the current status of trial NCT04474353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-21. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT04474353?
The interventions under investigation include: Temozolomide (DRUG), Gadolinium (DRUG), Optune (DEVICE), Stereotactic radiosurgery (SRS) (RADIATION).
Who is sponsoring clinical trial NCT04474353?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.